What Is The Current and Historic Market Size Analysis Of The Antidiabetics Market?
The antidiabetics market has seen considerable growth due to a variety of factors.
• The antidiabetics market has seen rapid growth in recent years. It will grow from $76.03 billion in 2024 to $84.84 billion in 2025, with a compound annual growth rate (CAGR) of 11.6%.
This expansion is driven by the rising global prevalence of diabetes, advances in drug development, increased awareness and diagnosis, supportive government policies, an aging population, sedentary lifestyles, and rising healthcare costs.
What Are The Predictions for The Antidiabetics Market in the Coming Years?
The antidiabetics market is expected to maintain its strong growth trajectory in upcoming years.
• The antidiabetics market is projected to grow quickly, reaching $130.12 billion by 2029 at a CAGR of 11.3%.
This growth is attributed to the rising prevalence of diabetes, better awareness and diagnosis, increasing healthcare spending, a growing elderly population, and supportive government policies. Trends in the market include the expansion of GLP-1 receptor agonists and SGLT2 inhibitors, the growth of biologics and biosimilars, a focus on preventive healthcare, emerging markets, and technological integration.
Which Drivers Are Accelerating Growth In The Antidiabetics Market?
The rising incidence of lifestyle-related conditions is expected to fuel the growth of the antidiabetics market. Lifestyle-related conditions, such as obesity and metabolic syndrome, are increasing due to poor diet, lack of exercise, and stress. Antidiabetic medications help manage these conditions by improving insulin sensitivity and controlling blood sugar levels. In 2022, the World Health Organization reported that obesity is rising globally, with an estimated 167 million adults and children expected to suffer from the health consequences of obesity by 2025. This trend is driving the antidiabetic market.
What Are The Core Segments Of The Global Antidiabetics Market?
The antidiabetics market covered in this report is segmented –
1) By Drug Class: Insulin, GLP-1 Receptor Agonists, DPP- 4 Inhibitors, SGLT2 Inhibitors, Other Drug Classes,
2) By Diabetes Type: Type 1, Type 2
3) By Patient Population: Antidiabetics For Pediatrics, Antidiabetics For Adults, Antidiabetics For Geriatrics
4) By Route Of Administration: Antidiabetics Administration Through Insulin Syringes Or Insulin Pens, Antidiabetics Administration Through Insulin Pumps, Intravenous Antidiabetics Infusion, Oral Antidiabetics Administration, Other Routes Of Antidiabetics Administration
5) By Distribution Channel: Online Pharmacies, Hospital Pharmacies, Retail Pharmacies
Subsegments:
1) By Insulin: Rapid-Acting Insulin, Short-Acting Insulin, Intermediate-Acting Insulin, Long-Acting Insulin, Premixed Insulin
2) By GLP-1 Receptor Agonists: Exenatide, Liraglutide, Dulaglutide, Semaglutide, Lixisenatide
3) By DPP-4 Inhibitors: Sitagliptin, Saxagliptin, Linagliptin, Alogliptin
4) By SGLT2 Inhibitors: Canagliflozin, Dapagliflozin, Empagliflozin, Ertugliflozin
5) By Other Drug Classes: Sulfonylureas, Thiazolidinediones (TZDs), Alpha-Glucosidase Inhibitors, Meglitinides, GLP-1/Insulin Combination Therapy
Pre-Book The Antidiabetics Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What New Trends Are Influencing The Antidiabetics Market?
Companies in the antidiabetics market are developing biosimilars to offer better treatment options for diabetes. For example, in January 2024, Glenmark Pharmaceuticals launched Lirafit, a biosimilar of the anti-diabetic drug Liraglutide. Clinical trials show it helps in glycemic control, weight loss, and improving cardiovascular safety for adults with type 2 diabetes.
Who Are the Key Players In The Antidiabetics Market?
Major companies operating in the antidiabetics market are:
• Pfizer Inc.
• Johnson & Johnson
• Merck & Co. Inc.
• Bayer AG
• Sanofi S.A.
• Bristol-Myers Squibb Company
• AstraZeneca plc
• Abbott Laboratories
• Novartis AG
• Takeda Pharmaceutical Company Limited
• GSK plc
• Eli Lilly and Company
• Amgen Inc.
• Boehringer Ingelheim International GmbH
• Gilead Sciences Inc.
• Novo Nordisk A/S
• Teva Pharmaceutical Industries Ltd.
• Regeneron Pharmaceuticals Inc.
• Astellas Pharma Inc.
• Biogen
• Vertex Pharmaceuticals Incorporated
• Servier Laboratories
• Sun Pharmaceutical Industries Limited
• Cipla Limited
• Dr. Reddy's Laboratories
• Lupin Limited
• Torrent Pharmaceuticals Ltd
• Biocon Limited
• Glenmark Pharmaceuticals Ltd.
What Are The Regional Insights Into The Antidiabetics Market?
North America was the largest region in the antidiabetics market in 2023. The regions covered in the antidiabetics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
